AlzeCure Pharma (Sweden) Today
| ALZCUR Stock | SEK 1.19 0.16 15.53% |
Performance0 of 100
| Odds Of DistressOver 84
|
AlzeCure Pharma is trading at 1.19 as of the 30th of November 2024, a 15.53% up since the beginning of the trading day. The stock's open price was 1.03. AlzeCure Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for AlzeCure Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
AlzeCure Pharma AB develops therapies for the treatment of Alzheimer s disease and related neurodegenerative disorders. The company was founded in 2012 and is based in Huddinge, Sweden. AlzeCure Pharma is traded on Stockholm Stock Exchange in Sweden. The company has 59.19 M outstanding shares. More on AlzeCure Pharma
Moving together with AlzeCure Stock
Moving against AlzeCure Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
AlzeCure Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AlzeCure Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AlzeCure Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
AlzeCure Pharma (ALZCUR) is traded on Stockholm Exchange in Sweden and employs 14 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 254.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AlzeCure Pharma's market, we take the total number of its shares issued and multiply it by AlzeCure Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AlzeCure Pharma operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 59.19 M outstanding shares.
AlzeCure Pharma has accumulated about 222.05 M in cash with (70.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.88, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check AlzeCure Pharma Probability Of Bankruptcy
Ownership AllocationAlzeCure Pharma holds a total of 59.19 Million outstanding shares. AlzeCure Pharma retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AlzeCure Ownership Details
AlzeCure Pharma Risk Profiles
Although AlzeCure Pharma's alpha and beta are two of the key measurements used to evaluate AlzeCure Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.04 | |||
| Standard Deviation | 4.28 | |||
| Variance | 18.34 | |||
| Risk Adjusted Performance | (0.13) |
AlzeCure Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in AlzeCure Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
AlzeCure Pharma Corporate Management
Elected by the shareholders, the AlzeCure Pharma's board of directors comprises two types of representatives: AlzeCure Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AlzeCure. The board's role is to monitor AlzeCure Pharma's management team and ensure that shareholders' interests are well served. AlzeCure Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AlzeCure Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marta MD | Chief Officer | Profile | |
| Martin Jnsson | Chief Officer | Profile | |
| Johan Sandin | Chief Officer | Profile | |
| Birgitta Lundvik | Chief Officer | Profile |
Other Information on Investing in AlzeCure Stock
AlzeCure Pharma financial ratios help investors to determine whether AlzeCure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AlzeCure with respect to the benefits of owning AlzeCure Pharma security.